Physician profile
Daniel A Ringold
NPI 1356562847
$2,186.57
in general payments reported to CMS, 2019-2025
12 companies · $403 in 2025
The $403 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.25 · 2020: $120 · 2021: $379 · 2022: $427 · 2023: $338 · 2024: $432 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,115.41 | 2019-2025 | Axios, Spyglass Discover, Spyglass |
| Abbvie INC. | $391.76 | 2021-2025 | Skyrizi, Rinvoq |
| Janssen Scientific Affairs, LLC | $242.59 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $114.10 | 2021 | |
| Amgen INC. | $79.81 | 2025 | Uplizna |
| Apollo Endosurgery US INC | $77.52 | 2022 | |
| Conmed Corporation | $64.50 | 2021-2023 | Conmed Hemostasis |
| Fujifilm Healthcare Americas Corporation | $28.83 | 2021 | |
| Janssen Biotech, INC. | $24.25 | 2025 | Tremfya |
| Shire North American Group INC | $23.14 | 2019 | |
| Steris Corporation | $12.53 | 2019 | |
| Ambu INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ringold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.